Oliver Lagore Vanvalin Investment Group Blueprint Medicines Corp Call Options Transaction History
Oliver Lagore Vanvalin Investment Group
- $359 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BPMC
# of Institutions
351Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$612 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$609 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$494 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$363 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$253 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.47B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...